Format

Send to

Choose Destination
See comment in PubMed Commons below
J Pharmacol Toxicol Methods. 2014 Nov-Dec;70(3):246-54. doi: 10.1016/j.vascn.2014.07.002. Epub 2014 Jul 31.

Prediction of Thorough QT study results using action potential simulations based on ion channel screens.

Author information

1
Computational Biology, Dept. of Computer Science, University of Oxford, Oxford OX1 3QD, UK. Electronic address: gary.mirams@cs.ox.ac.uk.
2
Clinical Informatics, R&D Information, AstraZeneca, Alderley Park, SK10 4TG, UK.
3
Screening & Compound Profiling, GlaxoSmithKline, Stevenage SG1 2NY, UK.
4
Discovery Sciences, AstraZeneca, Alderley Park, SK10 4TG, UK.
5
Safety Evaluation and Risk Management, Global Clinical Safety, GlaxoSmithKline, Middlesex UB11 1BT, UK.
6
Computational Biology, Dept. of Computer Science, University of Oxford, Oxford OX1 3QD, UK.
7
Translational Safety Department, Drug Safety & Metabolism, AstraZeneca, Alderley Park, SK10 4TG, UK.

Abstract

INTRODUCTION:

Detection of drug-induced pro-arrhythmic risk is a primary concern for pharmaceutical companies and regulators. Increased risk is linked to prolongation of the QT interval on the body surface ECG. Recent studies have shown that multiple ion channel interactions can be required to predict changes in ventricular repolarisation and therefore QT intervals. In this study we attempt to predict the result of the human clinical Thorough QT (TQT) study, using multiple ion channel screening which is available early in drug development.

METHODS:

Ion current reduction was measured, in the presence of marketed drugs which have had a TQT study, for channels encoded by hERG, CaV1.2, NaV1.5, KCNQ1/MinK, and Kv4.3/KChIP2.2. The screen was performed on two platforms - IonWorks Quattro (all 5 channels, 34 compounds), and IonWorks Barracuda (hERG & CaV1.2, 26 compounds). Concentration-effect curves were fitted to the resulting data, and used to calculate a percentage reduction in each current at a given concentration. Action potential simulations were then performed using the ten Tusscher and Panfilov (2006), Grandi et al. (2010) and O'Hara et al. (2011) human ventricular action potential models, pacing at 1Hz and running to steady state, for a range of concentrations.

RESULTS:

We compared simulated action potential duration predictions with the QT prolongation observed in the TQT studies. At the estimated concentrations, simulations tended to underestimate any observed QT prolongation. When considering a wider range of concentrations, and conventional patch clamp rather than screening data for hERG, prolongation of ≥5ms was predicted with up to 79% sensitivity and 100% specificity.

DISCUSSION:

This study provides a proof-of-principle for the prediction of human TQT study results using data available early in drug development. We highlight a number of areas that need refinement to improve the method's predictive power, but the results suggest that such approaches will provide a useful tool in cardiac safety assessment.

KEYWORDS:

Action potential; Cardiac safety; Compound screening; High-throughput; Mathematical model; Methods; Thorough QT

PMID:
25087753
PMCID:
PMC4266452
DOI:
10.1016/j.vascn.2014.07.002
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center